Revance Therapeutics (RVNC) Misses Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Join SI Premium – FREE
Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.37), $0.10 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $59.88 million versus the consensus estimate of $68.18 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pizza Hut CEO Aaron Powell resigns
- Raytheon wins $42.5M Navy air traffic contract
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
